![Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates: Molecular Therapy - Methods & Clinical Development Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/dee623ab-f652-4e99-a073-0eda99be0576/fx1_lrg.jpg)
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates: Molecular Therapy - Methods & Clinical Development
![Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters | Gene Therapy Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters | Gene Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41434-022-00380-z/MediaObjects/41434_2022_380_Fig1_HTML.png)
Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters | Gene Therapy
![Penn Medicine News on X: "Dr. James Wilson's deal with @amicusrx1 is named Deal of the Year. It formed a collaboration between Amicus and @PennMedicine's gene therapy program #PennInnovators2018 https://t.co/TBmlTXZV1N" / X Penn Medicine News on X: "Dr. James Wilson's deal with @amicusrx1 is named Deal of the Year. It formed a collaboration between Amicus and @PennMedicine's gene therapy program #PennInnovators2018 https://t.co/TBmlTXZV1N" / X](https://pbs.twimg.com/media/DtIBqxkU4AErAGR.jpg)
Penn Medicine News on X: "Dr. James Wilson's deal with @amicusrx1 is named Deal of the Year. It formed a collaboration between Amicus and @PennMedicine's gene therapy program #PennInnovators2018 https://t.co/TBmlTXZV1N" / X
Newly Approved Spinal Muscle Atrophy Treatment Zolgensma is Based on Delivery System Discovered by Penn Gene Therapy Pioneer - Penn Medicine
![Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia: Molecular Therapy - Methods & Clinical Development Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/1857b8e9-5d26-488d-8527-1983c58efcd2/fx1_lrg.jpg)
Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia: Molecular Therapy - Methods & Clinical Development
![Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration | Nature Biotechnology Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration | Nature Biotechnology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41587-023-01974-7/MediaObjects/41587_2023_1974_Fig1_HTML.png)
Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration | Nature Biotechnology
![Gene therapy pioneer Dr. James Wilson on what's next for the industry - Philadelphia Business Journal Gene therapy pioneer Dr. James Wilson on what's next for the industry - Philadelphia Business Journal](https://media.bizj.us/view/img/12340345/james-wilson-event-1*1200xx3200-1803-376-240.jpg)
Gene therapy pioneer Dr. James Wilson on what's next for the industry - Philadelphia Business Journal
![Pathogens | Free Full-Text | Fantastic AAV Gene Therapy Vectors and How to Find Them—Random Diversification, Rational Design and Machine Learning Pathogens | Free Full-Text | Fantastic AAV Gene Therapy Vectors and How to Find Them—Random Diversification, Rational Design and Machine Learning](https://www.mdpi.com/pathogens/pathogens-11-00756/article_deploy/html/images/pathogens-11-00756-g001.png)